Notice of Correction: Results of ACOSOG Z0050 trial: The utility of FDG-PET in staging potentially operable non–small cell lung cancer  by unknown
and International Organization for Standardization. The ru-
ral poor in the developing world continue to contract rheu-
matic heart disease and to need a durable inexpensive de-
vice that does not require anticoagulation.
For the dreamers, the road ahead is very hard. The
paradigm of valve development in the developed world does
not work for them. It is perhaps a moot point whether
rheumatic fever will be eradicated before a cheap and du-
rable device without requirement for anticoagulation is fi-
nally proven. I suspect that there will still be a reservoir of
patients needing the latter before the former is achieved.
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Notice of Correction
Results of ACOSOG Z0050 trial: The utility of FDG-PET in staging potentially operable
non–small cell lung cancer
To the Editor:
As the result of re-review of data from the American College of Surgeons Oncology Group Z0050
trial1 in preparation for an analysis of the use of brain FDG-PET in operable lung cancer, 2 some
corrections to the originally published data are reported. As published, FDG-PET correctly identified
M1 disease in 15 of 287 patients (5.2%). It was reported that in 19 of 287 evaluable patients (6.6%)
possible M1 disease was ruled out with confirmatory procedures (additional imaging or biopsy).
Re-review of the PET reports in this group revealed that two cases (1 brain, 1 bone) were erroneously
included by only blinded PET review and 4 cases (3 brain, 1 esophagus) were not suspicious per site
PET report re-read. It was also reported that M1 disease was indicated by PET in 8 additional patients
that the surgeon chose to overrule. Re-review shows that two cases (1 brain, 1 esophagus) were
erroneously included.
These corrections do not alter the conclusions of the ACOSOG Z0050 trial. However, the reported
percentage of patients with PET findings indicative of M1 disease subsequently proven not to be
metastatic decreases from 6.6% to 4.5%.
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